



## **Aurobindo Pharma receives USFDA tentative approval for Famciclovir Tablets**

31<sup>st</sup> January 2011

Aurobindo Pharma Limited is pleased to announce that the company has received tentative approval from the US Food & Drug Administration to manufacture and market Famciclovir Tablets 125mg, 250mg and 500mg

Famciclovir Tablets 125mg, 250mg and 500mg is the generic version of Novartis Pharmaceuticals Corp's Famvir® Tablets 125mg, 250mg and 500mg and is indicated for the treatment of recurrent mucocutaneous herpes simplex infections in HIV-infected patients and suppression of recurrent genital herpes in immunocompetent patients. The product has a market size of approximately US\$ 170 million for the twelve months ending September 2010 according to IMS

Aurobindo now has a total of 131 ANDA approvals (99 Final approvals and 32 Tentative approvals) from USFDA

### **About Aurobindo Pharma:**

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

### **For further information, please contact:**

Investor Relations  
Aurobindo Pharma Limited  
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad  
Phone: 040-66725000 / 66725401  
Email: [ir@aurobindo.com](mailto:ir@aurobindo.com)